RICARDO DANCEL: Open Payments
NPI 1164520631 · CHELMSFORD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,669 in 136 payments from 12 companies in 2025. Trend: 2023 $1,703 · 2024 $1,779 · 2025 $2,669
Food & beverage: $2,606Education: $63
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 22 | $477 |
| Vanda Pharmaceuticals Inc. | 27 | $373 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $360 |
| ABBVIE INC. | 17 | $314 |
| Alkermes, Inc. | 15 | $229 |
| Neurocrine BioSciences, Inc. | 7 | $222 |
| Janssen Pharmaceuticals, Inc | 7 | $221 |
| Lundbeck LLC | 8 | $173 |
| Teva Pharmaceuticals USA, Inc. | 9 | $151 |
| Otsuka America Pharmaceutical, Inc. | 4 | $98 |
Products named: COBENFY, FANAPT, CAPLYTA, VRAYLAR, REXULTI, INGREZZA, INVEGA SUSTENNA, ARISTADA.
Industry payments across MA — which companies pay providers there.
